Core Insights - Herantis Pharma has completed the last patient visit in the Phase 1b clinical trial for HER-096, a potential disease-modifying therapy for Parkinson's disease [1][2] - The company aims to analyze and interpret the data from the trial, with topline results expected in six to nine weeks [2][8] - HER-096 is designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF), promoting neuronal cell survival and functional recovery [2][10] Company Overview - Herantis Pharma is a clinical-stage biotechnology company focused on developing therapies for Parkinson's disease [12] - The lead product, HER-096, is a first-in-class small peptide molecule that combines neuroprotective mechanisms with subcutaneous administration [12] Clinical Trial Details - The Phase 1b study consists of two parts: Part 1 involved healthy volunteers receiving a single 300 mg dose to assess safety and pharmacokinetics, while Part 2 involved patients with Parkinson's disease receiving repeated doses [4][5] - The primary objective of the trial is to evaluate the safety, tolerability, and pharmacokinetics of HER-096, along with monitoring symptoms using established scales and wearable devices [6][8] - The trial is funded by The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK, and is being conducted in Finland [7][8] Disease Context - Parkinson's disease affects over 10 million people globally, with no approved therapies capable of stopping or slowing its progression [3] - Current treatments primarily address symptoms and often come with significant side effects [3] Mechanism of Action - HER-096 targets key drivers of neurodegeneration in Parkinson's disease by modulating the Unfolded Protein Response pathway and reducing neurotoxic protein aggregation [11] - The drug's ability to penetrate the blood-brain barrier enhances its potential to protect dopamine neurons and support their functional restoration [11]